CoChat

Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease

Open access
Milenkovic, Uros, Ilg, Marcus M., Cellek, Selim, Albersen, Maarten · 2019 · Sexual Medicine Reviews
Cited by 46

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Peyronie's disease (PD) is a debilitating affliction for the male population, causing severe curvatures to the erect penis and erectile dysfunction in about 50% of men. This deviation of the penis significantly impairs sexual intercourse and causes depression and strains in the relationship. As of today, medical treatment options are few and far between, with surgery remaining as the sole reliable treatment. AIM: To give a general overview regarding fibrosis and the specific role of extracellular matrix, macrophages, and myofibroblasts in PD. Additionally, we will provide an overview of past and present research and how this has shaped our vision concerning the pathophysiology of PD. METHODS: We performed a non-systematic literature review using the search terms "fibrosis," "pathophysiology," "myofibroblast," "extracellular matrix," "Peyronie's disease," and "drug discovery." MAIN OUTCOME MEASURE: We assessed current knowledge regarding fibrosis in PD and the possibility to use this knowledge for new treatment options. RESULTS: Interpreting findings from the most recent next-generation sequencing, in vitro and in vivo PD research, we provide novel insights for the pathophysiology of PD. Using this knowledge, we will attempt to provide future directions for PD research and drug discovery, which is urgently needed, because its treatment has essentially been stagnating for about 30 years. CONCLUSION: Historically, PD has not been studied as widely as kidney, lung, or hepatic fibrosis, and our knowledge of its pathophysiology still remains relatively obscure. Nonetheless, recent breakthroughs using stem cells, next-generation sequencing, and phenotypical screening assays bring us several steps closer to filling the gaps in our knowledge. In the near future, clinical trials will prove essential to translate this plethora of preclinical data into usable tools that can improve the lives of many of our patients. Milenkovic U, Ilg MM, Cellek S, et al. Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease. Sex Med Rev 2019;7:679-689.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.sxmr.2019.02.004

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 79

  1. Yafi, 2015, Therapeutic advances in the treatment of Peyronie’s disease, Andrology, 3, 650, 10.1111/andr.12058 · DOI
  2. Gelbard, 1990, The natural history of Peyronie’s disease, J Urol, 144, 1376
  3. Mulhall, 2006, An analysis of the natural history of Peyronie’s disease, J Urol, 175, 2115
  4. Kadioglu, 2007, Graft materials in Peyronie’s disease surgery: A comprehensive review, J Sex Med, 4, 581
  5. Mulhall, 2004, Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening, J Urol, 171, 2350
  6. Al-Thakafi, 2016, Peyronie’s disease: A literature review on epidemiology, genetics, pathophysiology, diagnosis and work-up, Transl Androl Urol, 5, 280, 10.21037/tau.2016.04.05 · DOI · Paper page
  7. Hatzichristodoulou, 2017, Contemporary review of grafting techniques for the surgical treatment of Peyronie’s disease, Sex Med, 5, 544
  8. Russo, 2018, Clinical efficacy of injection and mechanical therapy for Peyronie’s disease: A systematic review of the literature, Eur Urol, 74, 767, 10.1016/j.eururo.2018.07.005 · DOI · Paper page
  9. El-sakka, 1997, An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mrna and protein expression, J Urol, 158, 2284
  10. El-Sakka, 1998, Histological and ultrastructural alterations in an animal model of Peyronie’s disease, Br J Urol, 81, 445, 10.1046/j.1464-410x.1998.00529.x · DOI · Paper page
  11. Vernet, 2002, Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model, Nitric Oxide Biol Chem, 7, 262, 10.1016/S1089-8603(02)00124-6 · DOI
  12. Mulhall, 2002, Peyronie’s disease cell culture models: Phenotypic, genotypic and functional analyses, Int J Impot Res, 14, 397, 10.1038/sj.ijir.3900874 · DOI
  13. Valente, 2003, L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures, Nitric Oxide, 9, 229, 10.1016/j.niox.2003.12.002 · DOI · Paper page
  14. Mateus, 2018, Understanding the role of adenosine receptors in the myofibroblast transformation in Peyronie’s disease, J Sex Med, 15, 947
  15. Ilg, 2019, Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie’s disease models, Eur Urol, 75, 329, 10.1016/j.eururo.2018.10.014 · DOI · Paper page
  16. Milenkovic, 2019, Simvastatin and the rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie’s disease–derived fibroblasts via inhibition of YAP/TAZ nuclear translocation, BJU Int, 123, 703, 10.1111/bju.14638 · DOI · Paper page
  17. Gonzalez-Cadavid, 2004, Molecular pathophysiology and gene therapy of aging-related erectile dysfunction, Exp Gerontol, 39, 1705, 10.1016/j.exger.2004.06.022 · DOI
  18. Becker, 2001, Pharmacological intervention in renal fibrosis and vascular sclerosis, J Nephrol, 14, 332
  19. Gholami, 2003, Peyronie’s disease: A review, J Urol, 169, 1234
  20. Kim, 2016, Exercise-induced rhabdomyolysis mechanisms and prevention: A literature review, J Sport Heal Sci, 5, 324
  21. Duffield, 2013, Host responses in tissue repair and fibrosis, Annu Rev Pathol Mech Dis, 8, 241, 10.1146/annurev-pathol-020712-163930 · DOI · Paper page
  22. Lee, 2015, Pathobiology of liver fibrosis: A translational success story, Gut, 64, 830, 10.1136/gutjnl-2014-306842 · DOI · Paper page
  23. Noble, 2012, Pulmonary fibrosis: patterns and perpetrators, J Clin Invest, 122, 2756, 10.1172/JCI60323 · DOI · Paper page
  24. Smith, 2016, Update on pulmonary fibrosis: Not all fibrosis is created equally, Arch Pathol Lab Med, 140, 221, 10.5858/arpa.2015-0288-SA · DOI
  25. Liu, 2011, Cellular and molecular mechanisms of renal fibrosis, Nat Rev Nephrol, 7, 684, 10.1038/nrneph.2011.149 · DOI · Paper page
  26. Cannito, 2017, Therapeutic pro-fibrogenic signaling pathways in fibroblasts, Adv Drug Deliv Rev, 121, 57, 10.1016/j.addr.2017.05.017 · DOI
  27. Bollong, 2017, Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis, Proc Natl Acad Sci U S A, 114, 4679, 10.1073/pnas.1702750114 · DOI
  28. Tian, 2003, An HSV-TK transgenic mouse model to evaluate elimination of fibroblasts for fibrosis therapy, Am J Pathol, 163, 789, 10.1016/S0002-9440(10)63706-6 · doi:10.1016/s0002-9440(10)63706-6
  29. Hinz, 2015, The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship, Matrix Biol, 47, 54, 10.1016/j.matbio.2015.05.006 · DOI · Paper page
  30. Milenkovic, 2019, The mechanisms and potential of stem cell therapy for penile fibrosis, Nat Rev Urol, 16, 79, 10.1038/s41585-018-0109-7 · DOI
  31. Wynn, 2013, Macrophage biology in development, homeostasis and disease, Nature, 496, 445, 10.1038/nature12034 · DOI · Paper page
  32. McAnulty, 2007, Fibroblasts and myofibroblasts: Their source, function and role in disease, Int J Biochem Cell Biol, 39, 666, 10.1016/j.biocel.2006.11.005 · DOI · Paper page
  33. Parola, 2008, Myofibroblast-like cells and liver fibrogenesis: Emerging concepts in a rapidly moving scenario, Mol Aspects Med, 29, 58, 10.1016/j.mam.2007.09.002 · DOI · Paper page
  34. Hinz, 2012, Recent developments in myofibroblast biology, Am J Pathol, 180, 1340, 10.1016/j.ajpath.2012.02.004 · DOI · Paper page
  35. Novo, 2014, Cellular and molecular mechanisms in liver fibrogenesis, Arch Biochem Biophys, 548, 20, 10.1016/j.abb.2014.02.015 · DOI · Paper page
  36. Fernández, 2009, Angiogenesis in liver disease, J Hepatol, 50, 604, 10.1016/j.jhep.2008.12.011 · DOI · Paper page
  37. Gonzalez-Cadavid, 2009, Experimental models of Peyronie’s disease. Implications for new therapies, J Sex Med, 6, 303
  38. Wynn, 2008, Cellular and molecular mechanisms of fibrosis, J Pathol, 214, 199, 10.1002/path.2277 · DOI · Paper page
  39. Novo, 2007, Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells, Am J Pathol, 170, 1942, 10.2353/ajpath.2007.060887 · DOI · Paper page
  40. Udelson, 1998, Engineering analysis of penile hemodynamic and structural-dynamic relationships: Part II—Clinical implications of penile buckling, Int J Impot Res, 10, 25, 10.1038/sj.ijir.3900311 · DOI
  41. Udelson, 1999, Axial penile buckling forces vs Rigiscan radial rigidity as a function of intracavernosal pressure: Why Rigiscan does not predict functional erections in individual patients, Int J Impot Res, 11, 327, 10.1038/sj.ijir.3900443 · doi:10.1038/sj.ijir.3900443
  42. Martínez-Salamanca, 2016, α1A-Adrenergic receptor antagonism improves erectile and cavernosal responses in rats with cavernous nerve injury and enhances neurogenic responses in human corpus cavernosum from patients with erectile dysfunction secondary to radical prostatectomy, J Sex Med, 13, 1844
  43. Zargooshi, 2004, Trauma as the Cause of Peyronie’s Disease: Penile Fracture as a Model of Trauma, J Urol, 172, 186
  44. Gong, 2003, Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis, J Am Soc Nephrol, 14, 3047, 10.1097/01.ASN.0000098686.72971.DB · DOI · Paper page
  45. Davila, 2005, Peyronie’s disease associated with increase in plasminogen activator inhibitor in fibrotic plaque, Urology, 65, 645, 10.1016/j.urology.2005.01.010 · DOI
  46. Massagué, 2000, How cells read TGF-beta signals, Nat Rev Mol Cell Biol, 1, 169, 10.1038/35043051 · DOI · Paper page
  47. Tsou, 2014, Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription, Am J Physiol Cell Physiol, 307, C2, 10.1152/ajpcell.00060.2014 · DOI
  48. Ferrini, 2002, Antifibrotic role of inducible nitric oxide synthase, Nitric Oxide, 6, 283, 10.1006/niox.2001.0421 · DOI · Paper page
  49. Mulhall, 2003, Expanding the paradigm for plaque development in Peyronie’s disease, Int J Impot Res, 15, S93, 10.1038/sj.ijir.3901082 · DOI
  50. Ferrini, 2004, Aging-related induction of inducible nitric oxide synthase is vasculo-protective to the arterial media, Cardiovasc Res, 61, 796, 10.1016/j.cardiores.2003.12.006 · DOI · Paper page
  51. Ferrini, 2001, Aging-related expression of inducible nitric oxide synthase and markers of tissue damage in the rat penis, Biol Reprod, 64, 974, 10.1095/biolreprod64.3.974 · DOI · Paper page
  52. Castiglione, 2013, Intratunical injection of human adipose tissue–derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease, Eur Urol, 63, 551, 10.1016/j.eururo.2012.09.034 · DOI · Paper page
  53. Gokce, 2014, Adipose tissue–derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie’s disease, Andrology, 2, 244, 10.1111/j.2047-2927.2013.00181.x · DOI · Paper page
  54. Gokce, 2015, Intratunical injection of genetically modified adipose tissue-derived stem cells with human interferon α-2b for treatment of erectile dysfunction in a rat model of tunica albugineal fibrosis, J Sex Med, 12, 1533
  55. Jiang, 2017, Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells, Exp Ther Med, 14, 5149
  56. Castiglione, 2019, Intratunical injection of human adipose tissue–derived stem cells restores collagen III/I ratio in a rat model of chronic Peyronie’s disease, Sex Med, 7, 94, 10.1016/j.esxm.2018.09.003 · DOI
  57. Bias, 1982, Peyronie’s disease: A newly recognized autosomal-dominant trait, Am J Med Genet, 12, 227, 10.1002/ajmg.1320120213 · DOI · Paper page
  58. Willscher, 1979, The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease, J Urol, 122, 34
  59. Leffell, 1982, Non-association of Peyronie’s disease with HLA B7 cross-reactive antigens, J Urol, 127, 1223
  60. Deguchi, 1984, HLA-A and B antigens in patients with Peyronie disease, Urology, 23, 547, 10.1016/0090-4295(84)90068-2 · DOI
  61. Hauck, 2003, Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie’s disease, J Urol, 169, 369
  62. Awad, 1998, Genotypic variation in the transforming growth factor-beta1 gene: Association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation, Transplantation, 66, 1014, 10.1097/00007890-199810270-00009 · DOI · Paper page
  63. Dolmans, 2011, Wnt signaling and Dupuytren’s disease, N Engl J Med, 365, 307, 10.1056/NEJMoa1101029 · DOI · Paper page
  64. Magee, 2002, Gene expression profiles in the Peyronie’s disease plaque, Urology, 59, 451, 10.1016/S0090-4295(01)01578-3 · DOI
  65. Mori, 2000, Modulation of endogenous smad expression in normal skin fibroblasts by transforming growth factor-β, Exp Cell Res, 258, 374, 10.1006/excr.2000.4930 · DOI
  66. Kavsak, 2000, Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation, Mol Cell, 6, 1365, 10.1016/S1097-2765(00)00134-9 · DOI · Paper page
  67. Flordellis, 2006, Rethinking target discovery in polygenic diseases, Curr Top Med Chem, 6, 1791, 10.2174/156802606778194226 · DOI
  68. Nanthakumar, 2015, Dissecting fibrosis: Therapeutic insights from the small-molecule toolbox, Nat Rev Drug Discov, 14, 693, 10.1038/nrd4592 · DOI · Paper page
  69. Gonzalez-Cadavid, 2010, Treatment of Peyronie’s disease with PDE5 inhibitors: An antifibrotic strategy, Nat Rev Urol, 7, 215, 10.1038/nrurol.2010.24 · DOI
  70. Dellê, 2012, Antifibrotic effect of tamoxifen in a model of progressive renal disease, J Am Soc Nephrol, 23, 37, 10.1681/ASN.2011010046 · DOI
  71. Hauck, 2006, A critical analysis of nonsurgical treatment of Peyronie’s disease, Eur Urol, 49, 987, 10.1016/j.eururo.2006.02.059 · DOI
  72. Tsambarlis, 2018, Surgical management of Peyronie’s disease, Eur Urol Focus, 4, 304, 10.1016/j.euf.2018.08.026 · DOI
  73. Palmieri, 2012, Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: Results from a prospective randomized trial, Int J Androl, 35, 190, 10.1111/j.1365-2605.2011.01226.x · DOI · Paper page
  74. Dell’Atti, 2015, Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie’s disease, Urol Ann, 7, 345, 10.4103/0974-7796.152048 · DOI
  75. Ozturk, 2014, Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction, Irish J Med Sci, 183, 449, 10.1007/s11845-013-1036-5 · DOI
  76. Ralph, 1992, The treatment of Peyronie’s disease with Tamoxifen, Br J Urol, 648, 10.1111/j.1464-410X.1992.tb15836.x · DOI · Paper page
  77. Apaydin, 1998, The use of tamoxifen in the treatment of Peyronie’s disease, Int J Impot Res, 10, S57
  78. Teloken, 1999, Tamoxifen versus placebo in the treatment of Peyronie’s disease, J Urol, 162, 2003
  79. Marshall, 2013, Strategies for biomarker discovery in fibrotic disease, Biochim Biophys Acta, 1832, 1079, 10.1016/j.bbadis.2013.01.018 · DOI

Cited by

See all 46

Metadata

Authors
Milenkovic, U., Ilg, M. M., Cellek, S., & Albersen, M.
Venue
Sexual Medicine Reviews
Published
2019-10
Volume
7
Issue
4
Pages
679-689
ISSN
  • 2050-0513 (ISSN-L)
  • 2050-0521
OpenAlex
W2933207275
Cited by
46
References
28
FWCI
3.93
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease. https://app.cochat.ai/papers/10.1016/j.sxmr.2019.02.004
The paper
Milenkovic, U., Ilg, M. M., Cellek, S., & Albersen, M. (2019). Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie’s Disease. Sexual Medicine Reviews. https://doi.org/10.1016/j.sxmr.2019.02.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.